http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9169509-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-533 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-533 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2014-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04e70c1a4bbf29022f222153533f4ad9 |
| publicationDate | 2015-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9169509-B2 |
| titleOfInvention | Topoisomerase 2b as a predictor of susceptibility to anthracycline-induced cardiotoxicity |
| abstract | Biomarkers of anthracycline cardiotoxicity are provided. In certain aspects, methods are provided for determining whether a subject will develop cardiotoxicity upon treatment with an anthracycline, such as doxorubicin, by measuring the level of Top2b expression in the subject. In further aspects, methods of a treating a subjects with anthracycline therapeutics and cardioprotective agents are provided. |
| priorityDate | 2013-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1420.